Cyclacel Pharmaceuticals Inc (CYCC):企業の財務・戦略的SWOT分析

◆英語タイトル:Cyclacel Pharmaceuticals Inc (CYCC) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH37480FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥35,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥52,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Cyclacel Pharmaceuticals Inc (CYCC) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Cyclacel Pharmaceuticals Inc (Cyclacel) is a biopharmaceutical company that develops oral therapies. The company develops small molecule drugs that target various phases of cell cycle control for the treatment of cancer and other serious diseases. Its products include sapacitabine, seliciclib, CDK inhibitor and PLK inhibitor. Cyclacel’s sapacitabine is the drug candidate used to treat the patients with acute myeloid leukemia. The company’s seliciclib is an orally available, cyclin dependent kinase inhibitor. It offers products for the treatment of anti-infective, autoimmune, cardiovascular, ophthalmic and other non-oncology indications. The company operates in the US and the UK. Cyclacel is headquartered in Berkeley Heights, New Jersey, the US.

Cyclacel Pharmaceuticals Inc Key Recent Developments

Mar 16,2021: Cyclacel Pharmaceuticals Announces Closing of $14.5 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Mar 15,2021: Cyclacel to Present at the Oppenheimer 31st Annual Healthcare Conference
Feb 25,2021: Cyclacel Pharmaceuticals reports fourth quarter and full year 2020 financial results
Feb 19,2021: Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results
Feb 10,2021: Cyclacel Pharmaceuticals Announces Presentation at 2021 BIO CEO & Investor Digital Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Cyclacel Pharmaceuticals Inc – Key Facts
Cyclacel Pharmaceuticals Inc – Key Employees
Cyclacel Pharmaceuticals Inc – Key Employee Biographies
Cyclacel Pharmaceuticals Inc – Major Products and Services
Cyclacel Pharmaceuticals Inc – History
Cyclacel Pharmaceuticals Inc – Company Statement
Cyclacel Pharmaceuticals Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Cyclacel Pharmaceuticals Inc – Business Description
R&D Overview
Cyclacel Pharmaceuticals Inc – Corporate Strategy
Cyclacel Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Cyclacel Pharmaceuticals Inc – Strengths
Cyclacel Pharmaceuticals Inc – Weaknesses
Cyclacel Pharmaceuticals Inc – Opportunities
Cyclacel Pharmaceuticals Inc – Threats
Cyclacel Pharmaceuticals Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Cyclacel Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 15, 2021: Cyclacel to Present at the Oppenheimer 31st Annual Healthcare Conference
Feb 25, 2021: Cyclacel Pharmaceuticals reports fourth quarter and full year 2020 financial results
Feb 19, 2021: Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results
Feb 10, 2021: Cyclacel Pharmaceuticals Announces Presentation at 2021 BIO CEO & Investor Digital Conference
Jan 11, 2021: Cyclacel Pharmaceuticals reviews 2020 achievements and announces key business objectives for 2021
Dec 30, 2020: Cyclacel Pharmaceuticals to present at Biotech Showcase Digital 2021
Dec 21, 2020: Cyclacel Pharmaceuticals announces that Brian Schwartz, M.D. was elected to its board of directors
Nov 11, 2020: Cyclacel Pharmaceuticals reports third quarter 2020 financial results
Oct 23, 2020: Cyclacel Pharmaceuticals announces appointment of Mark Kirschbaum, M.D., as chief medical officer
Oct 05, 2020: Cyclacel Pharmaceuticals to present at the October 2020 Lytham Partners Virtual Investor Growth Conference
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Cyclacel Pharmaceuticals Inc, Key Facts
Cyclacel Pharmaceuticals Inc, Key Employees
Cyclacel Pharmaceuticals Inc, Key Employee Biographies
Cyclacel Pharmaceuticals Inc, Major Products and Services
Cyclacel Pharmaceuticals Inc, History
Cyclacel Pharmaceuticals Inc, Other Locations
Cyclacel Pharmaceuticals Inc, Subsidiaries
Cyclacel Pharmaceuticals Inc, Key Competitors
Cyclacel Pharmaceuticals Inc, Ratios based on current share price
Cyclacel Pharmaceuticals Inc, Annual Ratios
Cyclacel Pharmaceuticals Inc, Annual Ratios (Cont...1)
Cyclacel Pharmaceuticals Inc, Interim Ratios
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Cyclacel Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Cyclacel Pharmaceuticals Inc (CYCC):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NutriSystem Inc:企業の戦略的SWOT分析
    NutriSystem Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Braeburn Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Braeburn Pharmaceuticals Inc (Braeburn), a subsidiary of Apple Tree Partners is a pharmaceutical company that develops novel and long-acting implantable and injectable treatments.The company’s product pipeline includes Probuphine, CAM2038, BB-0417, BB-0817, BB-1216. Its Probuphine, is a a si …
  • Southwest Airlines Co:戦略・SWOT・企業財務分析
    Southwest Airlines Co - Strategy, SWOT and Corporate Finance Report Summary Southwest Airlines Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Caspian Sunrise Plc (CASP):石油・ガス:M&Aディール及び事業提携情報
    Summary Caspian Sunrise Plc (Caspian), formerly Roxi Petroleum plc, is an oil and gas exploration and development company. The company acquires, explores and develops crude oil. It holds interests in the exploration and production of BNG contract area in the Pre-Caspian basin and the Mangyshlak basi …
  • Harte Hanks Inc (HHS):企業の財務・戦略的SWOT分析
    Harte Hanks Inc (HHS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Oilex Ltd (OEX):石油・ガス:M&Aディール及び事業提携情報
    Summary Oilex Ltd (Oilex) is an oil and gas company that acquires, explores and develops petroleum resources. The company’s projects in Australia include STP-EPA-0106, STP-EPA-0131, and STP-EPA-0107. Its STP-EPA-0106 project is located in onshore north-western Australia. Oilex’s Indian projects are …
  • Caterpillar Inc.:戦略・SWOT・企業財務分析
    Caterpillar Inc. - Strategy, SWOT and Corporate Finance Report Summary Caterpillar Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Thai Airways International Public Co Ltd:企業の戦略・SWOT・財務情報
    Thai Airways International Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Thai Airways International Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Nihon Kohden Corporation:企業の戦略・SWOT・財務分析
    Nihon Kohden Corporation - Strategy, SWOT and Corporate Finance Report Summary Nihon Kohden Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Xylem Inc.:企業の戦略・SWOT・財務情報
    Xylem Inc. - Strategy, SWOT and Corporate Finance Report Summary Xylem Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • ABO-Group NV (ABO):企業の財務・戦略的SWOT分析
    Summary ABO-Group NV (ABO-Group), formerly Thenergo NV/SA, is a renewable energy service provider. It offers energy services, soil, environment, geotechnics and waste management services. The company’s services include consulting, training and monitoring services. Its soil services comprise groundwa …
  • Namibia Power Corporation (Proprietary) Ltd:企業の戦略的SWOT分析
    Namibia Power Corporation (Proprietary) Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ):企業の財務・戦略的SWOT分析
    Summary Eckert & Ziegler Strahlen- und Medizintechnik AG (Eckert & Ziegler) is a medical device company that offers isotope technology products. The company offers radiation therapy, isotope and radio-pharma products. It provides radiation therapy products for Brachytherapy, a minimally invasive pro …
  • Eli Lilly and Co (LLY):企業の財務・戦略的SWOT分析
    Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • TUV Nord AG:企業の戦略的SWOT分析
    TUV Nord AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • TransAlta Corp:企業の発電所・SWOT分析2018
    TransAlta Corp - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exe …
  • Kedrion SpA-製薬・医療分野:企業M&A・提携分析
    Summary Kedrion SpA (Kedrion) collects and fractionates blood plasma to develop, produce and distribute plasma-derived therapies. The company’s products are used for the treatment of rare and serious disorders such as hemophilia, immune deficiency and neurological disorders. It also offers products …
  • Halliburton Co (HAL):企業の財務・戦略的SWOT分析
    Halliburton Co (HAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • HTL International Holdings Limited:企業の戦略的SWOT分析
    HTL International Holdings Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Huge China Holdings Limited (428):企業の財務・戦略的SWOT分析
    Huge China Holdings Limited (428) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆